• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Hemorrhagic Fever - Pipeline Review, H2 2012 Product Image

Hemorrhagic Fever - Pipeline Review, H2 2012

  • ID: 2366330
  • December 2012
  • 56 pages
  • Global Markets Direct

Hemorrhagic Fever – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Hemorrhagic Fever - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Hemorrhagic Fever, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemorrhagic Fever. Hemorrhagic Fever - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hemorrhagic Fever.
- A review of the Hemorrhagic Fever products under development by companies and universities/research institutes READ MORE >

2
List of Tables 4
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Hemorrhagic Fever Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Hemorrhagic Fever 8
Hemorrhagic Fever Therapeutics under Development by Companies 10
Hemorrhagic Fever Therapeutics under Investigation by Universities/Institutes 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Discovery and Pre-Clinical Stage Products 14
Comparative Analysis 14
Hemorrhagic Fever Therapeutics – Products under Development by Companies 15
Hemorrhagic Fever Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Hemorrhagic Fever Therapeutics Development 17
Cangene Corporation 17
AVI BioPharma Inc. 18
Peregrine Pharmaceuticals, Inc. 19
Functional Genetics, Inc. 20
Evolva SA 21
Integrated BioTherapeutics, Inc. 22
Prosetta Corporation 23
Hemorrhagic Fever – Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Combination Products 25
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
AVI-6002 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
AVI-6003 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
EV-075 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
bavituximab - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ribavirin - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
bavituximab + [ribavirin] - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Ebola/Marburg Immune Globulins - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Filovirus Program - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Hantaan And Puumala Virus DNA Vaccine - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
AVI-7537 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
AVI-7288 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
PAV-667 Series - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
FGI-106 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Hemorrhagic Fever Therapeutics – Drug Profile Updates 45
Hemorrhagic Fever Therapeutics – Discontinued Products 51
Hemorrhagic Fever Therapeutics - Dormant Products 52
Hemorrhagic Fever – Product Development Milestones 53
Featured News & Press Releases 53
Oct 03, 2012: Sarepta Therapeutics Receives Notice From US Department Of Defense For Termination Of Ebola Therapeutic Program 53
Aug 02, 2012: Treatment With JPM-TMT Funded AVI-7288 Shows Significant Survival Rates Even When Administered Up To Four Days Post Infection 53
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 56
Disclaimer 56

List of Tables
Number of Products Under Development for Hemorrhagic Fever, H2 2012 8
Products under Development for Hemorrhagic Fever – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Cangene Corporation, H2 2012 17
AVI BioPharma Inc., H2 2012 18
Peregrine Pharmaceuticals, Inc., H2 2012 19
Functional Genetics, Inc., H2 2012 20
Evolva SA, H2 2012 21
Integrated BioTherapeutics, Inc., H2 2012 22
Prosetta Corporation, H2 2012 23
Assessment by Monotherapy Products, H2 2012 24
Assessment by Combination Products, H2 2012 25
Assessment by Stage and Route of Administration, H2 2012 27
Assessment by Stage and Molecule Type, H2 2012 29
Hemorrhagic Fever Therapeutics – Drug Profile Updates 45
Hemorrhagic Fever Therapeutics – Discontinued Products 51
Hemorrhagic Fever Therapeutics – Dormant Products 52

List of Figures
Number of Products under Development for Hemorrhagic Fever, H2 2012 8
Products under Development for Hemorrhagic Fever – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Discovery and Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 24
Assessment by Combination Products, H2 2012 25
Assessment by Route of Administration, H2 2012 26
Assessment by Stage and Route of Administration, H2 2012 27
Assessment by Molecule Type, H2 2012 28
Assessment by Stage and Molecule Type, H2 2012 29

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos